GC Aesthetics® (GCA®), the leading designer, manufacturer and distributor of breast implants and medical devices for the global aesthetics industry has announced its entry into the Chinese market in the Hainan Province, with two of its key products: Luna XT™ and PERLE™. This marks a significant milestone in the company’s expansion strategy, aimed at providing innovative aesthetic solutions for patients and surgeons worldwide.
China represents a rapidly growing market, the second largest worldwide, with an increasing demand for aesthetic enhancements. China’s aesthetic medicine market growth rate is higher than that of the global market, with revenue reaching 200 billion yuan ($27.6 billion). China’s medical aesthetics market expanded by 20% in 2023 and is expected to grow 15% annually*.
The evolving beauty standards and the cultural emphasis on personal appearance in China have opened an opportunity for GC Aesthetics to enter the market: Luna XT™ and PERLE™.
The new Luna XT™ Anatomical Breast Implant provides industry-leading support for women undergoing immediate and delayed breast reconstruction surgery. Its unique, microtextured surface, highly cohesive silicone gel and high-performance shell are a state-of-the-art option for women who wish to undergo breast procedures. Luna XT™ is available in a variety of projections, heights and volumes which makes it an all-rounder to suit different patients and their needs, it is also the first breast implant on the market under the latest Medical Device Regulation (MDR).
PERLE™ provides an industry-leading solution that features a revolutionary BioQ-Surface, Emunomic™ Breast Tissue Dynamic Gel and an advanced RRE patch to produce a smooth, opaque breast implant. The product was launched in Europe in 2021 and continues to be introduced in key markets including China. Its PERLE is highly respected by surgeons all over Europe and are quickly positioning the product to be the preferred type of breast implant surface.
Carlos Reis Pinto, CEO at GC Aesthetics®, said: “Our expansion into Hainan, in China is a testament to our dedication to meeting global demand with high-quality products. We are thrilled to partner with Gaoshi Group and look forward to a prosperous future in this dynamic market, offering patients safe, reliable and innovative products”
